EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review

Keith S Kaye iD, Anne Santerre Henriksen iD, Morten Sommer iD, Niels Frimodt-Møller iD

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae621 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Keith S Kaye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Urinary Tract Infections, Amdinocillin Pivoxil. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UTILITY therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent US Food and Drug Administration approval of pivmecillinam—an oral prodrug of the amidinopenicillin antibiotic mecillinam—presents a valuable opportunity to address the need for new treatments for uncomplicated urinary tract infection (uUTI). We report findings of a systematic literature review of the safety profile of pivmecillinam/mecillinam based on more than 40 years’ experience, mainly in Europe and Canada, to describe its tolerability profile and identify any important safety signals. In total, 110 eligible publications were identified describing use of pivmecillinam/mecillinam as monotherapy or in combination, for treatment of uUTI or other infectious conditions. These studies revealed a benign safety and tolerability profile, awareness of which will inform treatment decisions as pivmecillinam is made available in the United States. Together with the evidence for efficacy of, and minimal resistance to, pivmecillinam, the findings of this review support the position of pivmecillinam as a first-line treatment for uUTI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsUrinary Tract InfectionsAmdinocillin PivoxilHumansCanadaEuropeUnited States

Stichwörter der Autor:innen

antibioticmecillinampivmecillinamsafetyurinary tract infection

Substanzen

Anti-Bacterial AgentsAmdinocillin Pivoxil

Autor:innen und Institutionen

  • Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
  • Clinical Development, UTILITY therapeutics, London, United Kingdom.
  • Clinical Development, Maxel Consulting ApS, Jyllinge, Denmark.
  • DTU Biosustain, Technical University of Denmark, Lyngby, Denmark.
  • Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Keith S Kaye, Anne Santerre Henriksen, Morten Sommer, Niels Frimodt-Møller

Förderung

  • UTILITY therapeutics

Zitieren

APA

Kaye, K. S., Santerre Henriksen, A., Sommer, M., & Frimodt-Møller, N. (2025). Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae621

Vancouver

Kaye KS, Santerre Henriksen A, Sommer M, Frimodt-Møller N. Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae621

BibTeX
@article{Kaye2025,
  author = {Kaye, Keith S and Santerre Henriksen, Anne and Sommer, Morten and Frimodt-Møller, Niels},
  title = {Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae621}
}
Kostenlos starten →